Shares of Eli Lilly and Company (NYSE:LLY – Get Free Report) traded up 1.2% during trading on Friday. The stock traded as high as $1,449.64 and last traded at $1,444.05. Approximately 1,861,846 shares changed hands during trading, a decline of 37% from the average session volume of 2,956,564 shares. The stock had previously closed at $1,427.28.
Key Headlines Impacting Eli Lilly and Company
These are some of the LLY headlines that stood out recently:
- Positive Sentiment: Lilly broke ground on a $3.5 billion Pennsylvania manufacturing facility intended to make next-generation obesity medicines, including investigational retatrutide. The project supports the company’s broader production expansion, although the site is not expected to begin operations until 2031. Lilly announces Pennsylvania manufacturing facility
- Positive Sentiment: Hims & Hers will offer Lilly’s FDA-approved Zepbound and Foundayo, potentially extending patient reach through another care platform. Separately, exchange-traded funds were reported to have added to their Lilly holdings, signaling investor demand. Hims partners with Lilly to offer weight-loss drugs
- Negative Sentiment: China Merchants Securities downgraded Lilly from “buy” to “hold,” providing a cautionary view amid the positive product and capacity news. China Merchants Securities stock recommendations
Wall Street Analysts Forecast Growth
A number of equities research analysts have issued reports on LLY shares. The Goldman Sachs Group reiterated a “buy” rating and issued a $1,413.00 target price on shares of Eli Lilly and Company in a research report on Tuesday, October 20th. Citigroup boosted their price target on shares of Eli Lilly and Company from $1,600.00 to $1,650.00 and gave the company a “buy” rating in a report on Friday, October 30th. Scotiabank boosted their price target on shares of Eli Lilly and Company from $1,300.00 to $1,605.00 and gave the company a “sector outperform” rating in a report on Friday, October 30th. Morgan Stanley upped their price target on shares of Eli Lilly and Company from $1,430.00 to $1,596.00 and gave the stock an “overweight” rating in a research note on Friday, October 30th. Finally, Wells Fargo & Company increased their price objective on Eli Lilly and Company from $1,330.00 to $1,500.00 and gave the stock an “overweight” rating in a report on Friday, October 30th. One investment analyst has rated the stock with a Strong Buy rating, twenty-four have assigned a Buy rating, four have issued a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, Eli Lilly and Company has an average rating of “Moderate Buy” and an average price target of $1,416.64.
Read Our Latest Stock Report on Eli Lilly and Company
Eli Lilly and Company Price Performance
The company has a debt-to-equity ratio of 1.17, a current ratio of 1.39 and a quick ratio of 1.00. The stock has a market capitalization of $1.36 trillion, a price-to-earnings ratio of 46.87, a PEG ratio of 1.71 and a beta of 0.40. The stock’s 50 day simple moving average is $1,242.25 and its 200-day simple moving average is $1,110.30.
Eli Lilly and Company (NYSE:LLY – Get Free Report) last posted its earnings results on Thursday, October 29th. The company reported $7.48 EPS for the quarter, topping the consensus estimate of $5.71 by $1.77. Eli Lilly and Company had a net margin of 31.90% and a return on equity of 86.76%. The company had revenue of $24.40 billion during the quarter, compared to the consensus estimate of $22.58 billion. During the same period in the previous year, the firm posted $7.02 earnings per share. The company’s revenue for the quarter was up 38.6% compared to the same quarter last year. On average, analysts expect that Eli Lilly and Company will post 35.70 EPS for the current fiscal year.
Eli Lilly and Company Dividend Announcement
The business also recently declared a quarterly dividend, which will be paid on Thursday, December 10th. Stockholders of record on Friday, November 13th will be paid a dividend of $1.73 per share. This represents a $6.92 annualized dividend and a dividend yield of 0.5%. The ex-dividend date is Friday, November 13th. Eli Lilly and Company’s dividend payout ratio is 22.46%.
Insider Transactions at Eli Lilly and Company
In other Eli Lilly and Company news, EVP Patrik Jonsson sold 6,500 shares of the company’s stock in a transaction that occurred on Monday, August 17th. The stock was sold at an average price of $1,175.10, for a total transaction of $7,638,150.00. Following the completion of the sale, the executive vice president owned 54,147 shares of the company’s stock, valued at $63,628,139.70. This represents a 10.72% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Anat Hakim sold 5,000 shares of the company’s stock in a transaction that occurred on Monday, November 2nd. The stock was sold at an average price of $1,402.52, for a total value of $7,012,600.00. Following the sale, the executive vice president directly owned 4,137 shares of the company’s stock, valued at $5,802,225.24. The trade was a 54.72% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Corporate insiders own 0.14% of the company’s stock.
Institutional Inflows and Outflows
Hedge funds and other institutional investors have recently bought and sold shares of the company. Marshall & Sterling Wealth Advisors Inc. increased its stake in shares of Eli Lilly and Company by 60.0% in the first quarter. Marshall & Sterling Wealth Advisors Inc. now owns 40 shares of the company’s stock worth $37,000 after purchasing an additional 15 shares during the period. Torren Management LLC boosted its stake in Eli Lilly and Company by 357.1% during the 3rd quarter. Torren Management LLC now owns 32 shares of the company’s stock valued at $37,000 after purchasing an additional 25 shares during the period. AlphaCentric Advisors LLC bought a new stake in Eli Lilly and Company during the 1st quarter valued at approximately $42,000. Foresight Capital Management Advisors Inc. acquired a new stake in Eli Lilly and Company in the 3rd quarter valued at approximately $49,000. Finally, Sumitomo Mitsui Financial Group Inc. increased its position in Eli Lilly and Company by 5,100.0% in the 3rd quarter. Sumitomo Mitsui Financial Group Inc. now owns 52 shares of the company’s stock worth $60,000 after buying an additional 51 shares during the period. 82.53% of the stock is currently owned by institutional investors and hedge funds.
About Eli Lilly and Company
Eli Lilly and Company is a global pharmaceutical company that discovers, develops, manufactures and markets medicines for people and animals. Its work spans areas including diabetes and obesity, cancer, immunology, neuroscience and pain management. The company’s medicines include treatments for diabetes and obesity, such as Mounjaro and Zepbound, as well as products for cancer and other conditions. Lilly also conducts research into new medicines and invests in the development of treatments across its therapeutic areas.
Featured Articles
- Five stocks we like better than Eli Lilly and Company
- Intuitive Machines’ Business Is Taking Off—Will Its Stock Follow?
- The Next Big Thing May Not Be One Thing: Inside Lazard’s Megatrends ETF
- 3 Power and Grid Stocks That Could Keep Growing Even if AI Spending Slows
- Applied Materials Beats and Raises, But Investors Stay Unconvinced
Receive News & Ratings for Eli Lilly and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and Company and related companies with MarketBeat.com's FREE daily email newsletter.
